Core Viewpoint - The company reported significant growth in both revenue and net profit for the fiscal year 2025, indicating strong operational performance and effective management strategies [1] Financial Performance - The company achieved total revenue of 1.044 billion yuan, representing a year-on-year increase of 29.52% [1] - The net profit attributable to shareholders reached 272 million yuan, marking a substantial year-on-year growth of 117.72% [1] - As of the end of the reporting period, total assets amounted to 3.659 billion yuan, reflecting a growth of 5.58% compared to the beginning of the period [1] Business Development - The company's product collection and procurement have led to a sustained release of growth potential [1] - International business operations are progressing steadily, contributing to revenue growth [1] - The company continues to optimize operational management and resource allocation, enhancing operational efficiency and profitability [1]

Core Viewpoint - Spring Medical (688236.SH) reported a significant increase in both revenue and net profit for the fiscal year 2025, indicating strong business performance and growth potential [1] Financial Performance - The company achieved total operating revenue of 1.044 billion yuan, representing a year-on-year growth of 29.52% [1] - The net profit attributable to the parent company was 272 million yuan, reflecting a substantial year-on-year increase of 117.72% [1] Business Development - The growth potential of the company's products has been continuously released following the implementation of centralized procurement [1] - The international business is steadily advancing, contributing to the overall revenue growth [1] - Internal and external collaboration has driven stable revenue growth [1] Operational Efficiency - The company has been optimizing its management and resource allocation, leading to improved operational efficiency and profitability [1] - These enhancements have collectively supported the achievement of strong performance growth [1]

Core Viewpoint - The company achieved a total operating revenue of 1.044 billion yuan in 2025, representing a year-on-year growth of 29.52% [1] - The net profit reached 272 million yuan, with a significant year-on-year increase of 117.72% [1] Group 1: Revenue Growth - The company's product collection has led to a sustained release of growth potential [1] - The international business is steadily advancing, contributing to revenue stability [1] Group 2: Operational Efficiency - Continuous optimization of management and resource allocation has enhanced operational efficiency [1] - Improved profitability has collectively driven the company's performance to achieve good growth [1]

Group 1 - The core driving force of the company's development is its internationalization strategy [1] - The company is actively advancing its overseas market layout [1] - The company's products have been sold to multiple countries and regions worldwide, including EU member states [1]

Core Viewpoint - The company emphasizes its internationalization strategy as a core driver of its development, actively expanding its overseas market presence, including sales to EU member countries [1]. Group 1 - The company has responded to investor inquiries regarding its exports to EU countries, confirming that its products are sold in multiple countries and regions globally, including EU member states [1].